Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis
| Autor: | B Mahe, M. Leterrier, Thomas Guimard, J. Mahe, David Boutoille, M. Morrier, J. Brochard, F. Morio, P. Le Pape, François Raffi |
|---|---|
| Přispěvatelé: | Cibles et médicaments de l'infection, de l'immunité et du cancer (IICiMed), Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN) |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.drug_class Chronic lymphocytic leukemia [SDV]Life Sciences [q-bio] Tyrosine-kinase inhibitor 03 medical and health sciences chemistry.chemical_compound Piperidines Risk Factors Internal medicine Pharmacovigilance medicine Humans In patient Risk factor Protein Kinase Inhibitors 0303 health sciences 030306 microbiology business.industry Adenine Cryptococcosis medicine.disease Leukemia Lymphocytic Chronic B-Cell 3. Good health Infectious Diseases chemistry Ibrutinib business Bruton's tyrosine kinase inhibitor |
| Zdroj: | Médecine et Maladies Infectieuses Médecine et Maladies Infectieuses, Elsevier Masson, 2020, 50, pp.742-745. ⟨10.1016/j.medmal.2020.07.005⟩ |
| ISSN: | 0399-077X |
| Popis: | Purpose Invasive fungal diseases and especially Cryptococcus neoformans infections are increasingly reported in patients with hematological malignancies receiving ibrutinib, a Bruton's tyrosine kinase inhibitor. Patients and method We reported three additional cases and reviewed 16 previous published cases together with cases from the international pharmacovigilance database. Results Patients were mainly treated for chronic lymphocytic leukemia. Cryptococcosis mostly occurred during the first six months (66%) and especially the first two months (44%) of treatment. Clinical presentation is often pulmonary (68%) and the outcome is usually favorable despite ibrutinib continuation. Conclusion Clinicians must be aware of this infection in patients with hematological malignancies on ibrutinib. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect